Open Payments

MOSES SUNDAR RAJ

Type
Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
Where
DENVER, NC
NPI
1992707418
Received
$132,210 in 193 records, 2019 to 2025
As principal investigator
$2,468,843 of research payments to others in 232 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment37$33,332
2024General payment41$23,848
2023General payment24$17,486
2022General payment23$18,771
2021General payment16$13,040
2020General payment16$9,257
2019General payment36$16,472

By company

CompanyRecordsAmountYears
E.R. Squibb & Sons, L.L.C.79$101,5922019–2025
AstraZeneca Pharmaceuticals LP40$13,9562019–2024
Deciphera Pharmaceuticals Inc.7$3,8302024–2025
AVYXA PHARMA, LLC4$2,3672025
Astellas Pharma US Inc5$2,3412025
Takeda Pharmaceuticals U.S.A., Inc.1$2,0402025
Exelixis Inc.2$1,9942019
Celgene Corporation4$1,5132022–2023
Inari Medical, Inc.2$3522022–2024
Intera Oncology, Inc2$3152021–2023
Janssen Biotech, Inc.3$2202025
Pulmonx Corporation1$1692025
Mirati Therapeutics, Inc.2$1572023
Intuitive Surgical, Inc.1$1312024
Incyte Corporation2$1292025
Novocure Inc.1$1292020
EMD Serono, Inc.1$1212023
Iovance Biotherapeutics, Inc.1$1202024
Genentech USA, Inc.8$1152019–2025
Medtronic, Inc.1$1112023
Regeneron Healthcare Solutions, Inc.3$582023–2025
GENZYME CORPORATION2$502023–2025
Bayer Healthcare Pharmaceuticals Inc.3$492019
Merck Sharp & Dohme LLC3$462019–2023
Gilead Sciences, Inc.1$392019
Acrotech Biopharma Inc.2$382021–2024
Lilly USA, LLC2$342019–2025
Aurobindo Pharma USA, Inc.1$262020
SEAGEN INC.2$242019
SERVIER PHARMACEUTICALS LLC1$242025
TerSera Therapeutics LLC1$242025
Clovis Oncology, Inc.2$242019
ARRAY BIOPHARMA INC1$222025
Amgen Inc.1$192023
Novartis Pharmaceuticals Corporation1$162024

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v20$87,391
Consulting Fee33$30,762
Food and Beverage118$7,545
Travel and Lodging14$3,295
Honoraria1$3,000
Education7$216

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-18SERVIER PHARMACEUTICALS LLC$24Food and BeverageIn-kind items and servicesTibsovo Drug, Oncology2025
2025-12-16GENZYME CORPORATION$31Food and BeverageIn-kind items and servicesSARCLISA Biological, Oncology2025
2025-12-08Incyte Corporation$99EducationCash or cash equivalent2025
2025-12-04Genentech USA, Inc.$25Food and BeverageIn-kind items and servicesVenclexta Biological, BioOncology2025
2025-12-02TerSera Therapeutics LLC$24Food and BeverageIn-kind items and servicesQuzyttir Drug, Acute Care2025
2025-11-21Janssen Biotech, Inc.$56Food and BeverageIn-kind items and servicesTECVAYLI Biological, Oncology2025
2025-11-18Regeneron Healthcare Solutions, Inc.$24Food and BeverageIn-kind items and servicesLIBTAYO Biological, ONCOLOGY2025
2025-11-14Deciphera Pharmaceuticals Inc.$24Food and BeverageIn-kind items and servicesQINLOCK Drug, ONCOLOGY2025
2025-11-08AVYXA PHARMA, LLC$2,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-11-08AVYXA PHARMA, LLC$177Food and BeverageIn-kind items and services2025
2025-11-08AVYXA PHARMA, LLC$100Travel and LodgingIn-kind items and services2025
2025-11-08AVYXA PHARMA, LLC$89Food and BeverageIn-kind items and services2025
2025-10-31Incyte Corporation$29Food and BeverageCash or cash equivalentJAKAFI Drug, Hematology/Oncology2025
2025-10-28Janssen Biotech, Inc.$30Food and BeverageIn-kind items and servicesERLEADA Drug, Oncology2025
2025-10-28Lilly USA, LLC$23Food and BeverageIn-kind items and servicesVERZENIO Drug, Oncology2025
2025-10-21ARRAY BIOPHARMA INC$22Food and BeverageIn-kind items and servicesLORBRENA Drug, ONCOLOGY2025
2025-10-08E.R. Squibb & Sons, L.L.C.$6,370Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2025
2025-10-01E.R. Squibb & Sons, L.L.C.$6,370Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2025
2025-09-18E.R. Squibb & Sons, L.L.C.$124Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2025
2025-09-10E.R. Squibb & Sons, L.L.C.$114Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2025
2025-09-10E.R. Squibb & Sons, L.L.C.$15Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2025
2025-07-21E.R. Squibb & Sons, L.L.C.$1,820Consulting FeeCash or cash equivalent2025
2025-06-12E.R. Squibb & Sons, L.L.C.$455Consulting FeeCash or cash equivalent2025
2025-05-29Janssen Biotech, Inc.$133Food and BeverageIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-05-15E.R. Squibb & Sons, L.L.C.$1,820Consulting FeeCash or cash equivalent2025
2025-04-14Astellas Pharma US Inc$2,000Consulting FeeCash or cash equivalentVyloy Drug, Oncology2025
2025-04-14E.R. Squibb & Sons, L.L.C.$5Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2025
2025-04-10E.R. Squibb & Sons, L.L.C.$455Consulting FeeCash or cash equivalent2025
2025-04-04Astellas Pharma US Inc$266Travel and LodgingCash or cash equivalentVyloy Drug, Oncology2025
2025-04-04Astellas Pharma US Inc$44Food and BeverageIn-kind items and servicesVyloy Drug, Oncology2025
2025-04-04Astellas Pharma US Inc$18Travel and LodgingCash or cash equivalentVyloy Drug, Oncology2025
2025-04-04Astellas Pharma US Inc$12Food and BeverageIn-kind items and servicesVyloy Drug, Oncology2025
2025-03-25E.R. Squibb & Sons, L.L.C.$6,370Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2025
2025-03-18Pulmonx Corporation$169Food and BeverageIn-kind items and servicesCHARTIS CATHETER Device, PULMONOLOGY2025
2025-03-11Takeda Pharmaceuticals U.S.A., Inc.$2,040Consulting FeeCash or cash equivalentFRUZAQLA Drug, ONCOLOGY2025
2025-03-05E.R. Squibb & Sons, L.L.C.$124Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2025
2025-02-25E.R. Squibb & Sons, L.L.C.$1,820Consulting FeeCash or cash equivalent2025
2024-12-11E.R. Squibb & Sons, L.L.C.$6,278Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentAUGTYRO Drug, Oncology2024
2024-11-21AstraZeneca Pharmaceuticals LP$115Food and BeverageIn-kind items and services2024
2024-11-07E.R. Squibb & Sons, L.L.C.$804Travel and LodgingCash or cash equivalentAUGTYRO Drug, Oncology2024
2024-11-07E.R. Squibb & Sons, L.L.C.$121Food and BeverageCash or cash equivalentAUGTYRO Drug, Oncology2024
2024-11-05E.R. Squibb & Sons, L.L.C.$3Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2024
2024-10-24E.R. Squibb & Sons, L.L.C.$7Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2024
2024-10-22AstraZeneca Pharmaceuticals LP$114Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2024
2024-10-14AstraZeneca Pharmaceuticals LP$106Food and BeverageIn-kind items and services2024
2024-10-10E.R. Squibb & Sons, L.L.C.$600Consulting FeeCash or cash equivalent2024
2024-10-09E.R. Squibb & Sons, L.L.C.$5,137Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2024
2024-09-27E.R. Squibb & Sons, L.L.C.$300Consulting FeeCash or cash equivalent2024
2024-09-18E.R. Squibb & Sons, L.L.C.$100Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2024
2024-08-06E.R. Squibb & Sons, L.L.C.$5Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2024
2024-08-06E.R. Squibb & Sons, L.L.C.$3Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2024
2024-08-01AstraZeneca Pharmaceuticals LP$1,110Consulting FeeCash or cash equivalentIMFINZI Biological, Oncology2024
2024-08-01AstraZeneca Pharmaceuticals LP$1,110Consulting FeeCash or cash equivalent2024
2024-07-30AstraZeneca Pharmaceuticals LP$244Travel and LodgingIn-kind items and servicesIMFINZI Biological, Oncology2024
2024-07-30AstraZeneca Pharmaceuticals LP$13Travel and LodgingCash or cash equivalentIMFINZI Biological, Oncology2024
2024-07-26AstraZeneca Pharmaceuticals LP$244Travel and LodgingIn-kind items and servicesIMFINZI Biological, Oncology2024
2024-07-26AstraZeneca Pharmaceuticals LP$41Food and BeverageCash or cash equivalentIMFINZI Biological, Oncology2024
2024-07-26AstraZeneca Pharmaceuticals LP$39Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2024
2024-07-26AstraZeneca Pharmaceuticals LP$13Travel and LodgingCash or cash equivalentIMFINZI Biological, Oncology2024
2024-07-24Regeneron Healthcare Solutions, Inc.$17EducationIn-kind items and servicesLIBTAYO Biological, ONCOLOGY2024
2024-07-02AstraZeneca Pharmaceuticals LP$525Consulting FeeCash or cash equivalentTAGRISSO Drug, Oncology2024
2024-06-26AstraZeneca Pharmaceuticals LP$122Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2024
2024-06-18E.R. Squibb & Sons, L.L.C.$600Consulting FeeCash or cash equivalent2024
2024-06-13AstraZeneca Pharmaceuticals LP$124Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2024
2024-05-22AstraZeneca Pharmaceuticals LP$525Consulting FeeCash or cash equivalentIMFINZI Biological, Oncology2024
2024-05-13Iovance Biotherapeutics, Inc.$120Food and BeverageCash or cash equivalentAmtagvi Drug, Oncology2024
2024-04-25Deciphera Pharmaceuticals Inc.$3,000HonorariaCash or cash equivalentQINLOCK Drug, ONCOLOGY2024
2024-04-25Deciphera Pharmaceuticals Inc.$44Travel and LodgingCash or cash equivalentQINLOCK Drug, ONCOLOGY2024
2024-03-26Intuitive Surgical, Inc.$131Food and BeverageIn-kind items and servicesDa Vinci Surgical System Device, SURGERY2024
2024-03-21Inari Medical, Inc.$195Food and BeverageIn-kind items and servicesFLOWTRIEVER CATHETER, S Device, VTE2024
2024-03-06Novartis Pharmaceuticals Corporation$16Food and BeverageIn-kind items and servicesSCEMBLIX Drug, Oncology2024
2024-02-26E.R. Squibb & Sons, L.L.C.$4Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2024
2024-02-20E.R. Squibb & Sons, L.L.C.$1,120Consulting FeeCash or cash equivalent2024
2024-02-14Acrotech Biopharma Inc.$24Food and BeverageIn-kind items and servicesBELEODAQ Drug, ONCOLOGY2024
2024-01-29Deciphera Pharmaceuticals Inc.$114Food and BeverageCash or cash equivalentQINLOCK Drug, ONCOLOGY2024
2024-01-29Deciphera Pharmaceuticals Inc.$87Food and BeverageCash or cash equivalentQINLOCK Drug, ONCOLOGY2024
2024-01-18Deciphera Pharmaceuticals Inc.$409Travel and LodgingCash or cash equivalentQINLOCK Drug, ONCOLOGY2024
2024-01-12Deciphera Pharmaceuticals Inc.$150Travel and LodgingCash or cash equivalentQINLOCK Drug, ONCOLOGY2024
2023-12-29E.R. Squibb & Sons, L.L.C.$600Consulting FeeCash or cash equivalent2023
2023-12-19E.R. Squibb & Sons, L.L.C.$5,137Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2023
2023-12-14E.R. Squibb & Sons, L.L.C.$5Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2023
2023-11-22E.R. Squibb & Sons, L.L.C.$5,137Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2023
2023-11-16E.R. Squibb & Sons, L.L.C.$117Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2023
2023-11-10E.R. Squibb & Sons, L.L.C.$131Food and BeverageCash or cash equivalent2023
2023-11-10E.R. Squibb & Sons, L.L.C.$22Food and BeverageCash or cash equivalent2023
2023-11-10Merck Sharp & Dohme LLC$19EducationIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2023
2023-11-01E.R. Squibb & Sons, L.L.C.$123Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2023
2023-10-26E.R. Squibb & Sons, L.L.C.$18Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2023
2023-10-26Celgene Corporation$13Food and BeverageCash or cash equivalentREBLOZYL Biological, Hematology2023
2023-10-25AstraZeneca Pharmaceuticals LP$127Food and BeverageIn-kind items and services2023
2023-10-17E.R. Squibb & Sons, L.L.C.$5,137Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2023
2023-09-27E.R. Squibb & Sons, L.L.C.$58Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2023
2023-06-16Medtronic, Inc.$111Food and BeverageIn-kind items and servicesABRE Device, Stents2023
2023-06-15E.R. Squibb & Sons, L.L.C.$93Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2023
2023-06-06Intera Oncology, Inc$162Food and BeverageIn-kind items and servicesIntera 3000 Implantable Pump Device, Oncology2023
2023-05-24AstraZeneca Pharmaceuticals LP$133Food and BeverageIn-kind items and services2023
2023-05-23Amgen Inc.$19Food and BeverageIn-kind items and servicesKyprolis Drug, Oncology2023
2023-05-10Regeneron Healthcare Solutions, Inc.$17Food and BeverageIn-kind items and servicesLIBTAYO Biological, ONCOLOGY2023
2023-05-09GENZYME CORPORATION$18Food and BeverageIn-kind items and servicesJEVTANA Drug, Oncology2023
2023-03-03Mirati Therapeutics, Inc.$115Food and BeverageCash or cash equivalentKRAZATI Drug, ONCOLOGY2023
2023-02-21Mirati Therapeutics, Inc.$42EducationIn-kind items and servicesKRAZATI Drug, ONCOLOGY2023
2023-01-31EMD Serono, Inc.$121Food and BeverageCash or cash equivalentTEPMETKO Drug, Oncology2023
2022-11-29E.R. Squibb & Sons, L.L.C.$4,780Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2022
2022-11-21E.R. Squibb & Sons, L.L.C.$4,780Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2022
2022-11-17Inari Medical, Inc.$157Food and BeverageIn-kind items and servicesFLOWTRIEVER CATHETER, S Device, VTE2022
2022-11-10E.R. Squibb & Sons, L.L.C.$96Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2022
2022-11-03E.R. Squibb & Sons, L.L.C.$120Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2022
2022-09-06E.R. Squibb & Sons, L.L.C.$300Consulting FeeCash or cash equivalent2022
2022-06-15Celgene Corporation$300Consulting FeeCash or cash equivalent2022
2022-06-15E.R. Squibb & Sons, L.L.C.$300Consulting FeeCash or cash equivalent2022
2022-06-15E.R. Squibb & Sons, L.L.C.$300Consulting FeeCash or cash equivalent2022
2022-06-05AstraZeneca Pharmaceuticals LP$4,162Consulting FeeCash or cash equivalentIMFINZI Biological, Oncology2022
2022-06-01Celgene Corporation$600Consulting FeeCash or cash equivalent2022
2022-06-01E.R. Squibb & Sons, L.L.C.$300Consulting FeeCash or cash equivalent2022
2022-05-21AstraZeneca Pharmaceuticals LP$170Travel and LodgingIn-kind items and servicesIMFINZI Biological, Oncology2022
2022-05-20AstraZeneca Pharmaceuticals LP$623Travel and LodgingIn-kind items and servicesIMFINZI Biological, Oncology2022
2022-05-20AstraZeneca Pharmaceuticals LP$192Travel and LodgingIn-kind items and servicesIMFINZI Biological, Oncology2022
2022-05-20AstraZeneca Pharmaceuticals LP$152Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2022
2022-05-20AstraZeneca Pharmaceuticals LP$50Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2022
2022-05-20AstraZeneca Pharmaceuticals LP$34Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2022
2022-05-20AstraZeneca Pharmaceuticals LP$25Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2022
2022-05-20AstraZeneca Pharmaceuticals LP$25Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2022
2022-03-30Celgene Corporation$600Consulting FeeCash or cash equivalent2022
2022-03-30E.R. Squibb & Sons, L.L.C.$600Consulting FeeCash or cash equivalent2022
2022-02-24AstraZeneca Pharmaceuticals LP$102Food and BeverageIn-kind items and servicesTAGRISSO Drug, Oncology2022
2021-12-07E.R. Squibb & Sons, L.L.C.$4,505Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2021
2021-12-06Intera Oncology, Inc$153Food and BeverageIn-kind items and servicesIntera 3000 Hepatic Artery Infusion Pump Device, Oncology2021
2021-11-10E.R. Squibb & Sons, L.L.C.$76Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2021
2021-07-14E.R. Squibb & Sons, L.L.C.$76Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2021
2021-07-12E.R. Squibb & Sons, L.L.C.$600Consulting FeeCash or cash equivalent2021
2021-07-08E.R. Squibb & Sons, L.L.C.$600Consulting FeeCash or cash equivalent2021
2021-07-01E.R. Squibb & Sons, L.L.C.$300Consulting FeeCash or cash equivalent2021
2021-06-30AstraZeneca Pharmaceuticals LP$109Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2021
2021-06-29E.R. Squibb & Sons, L.L.C.$4,505Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2021
2021-06-28E.R. Squibb & Sons, L.L.C.$600Consulting FeeCash or cash equivalent2021
2021-06-09E.R. Squibb & Sons, L.L.C.$83Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2021
2021-05-18E.R. Squibb & Sons, L.L.C.$1,400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2021
2021-05-14E.R. Squibb & Sons, L.L.C.$4Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2021
2021-05-14E.R. Squibb & Sons, L.L.C.$2Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2021
2021-03-18Acrotech Biopharma Inc.$13EducationIn-kind items and servicesBELEODAQ Drug, ONCOLOGY2021
2021-03-18E.R. Squibb & Sons, L.L.C.$11EducationIn-kind items and servicesOPDIVO Biological, Oncology2021
2020-12-08E.R. Squibb & Sons, L.L.C.$3,505Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2020
2020-11-18AstraZeneca Pharmaceuticals LP$124Food and BeverageIn-kind items and servicesIMFINZI Drug, Oncology2020
2020-10-21E.R. Squibb & Sons, L.L.C.$117Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2020
2020-09-03AstraZeneca Pharmaceuticals LP$80Food and BeverageIn-kind items and servicesIMFINZI Drug, Oncology2020
2020-07-28E.R. Squibb & Sons, L.L.C.$250Consulting FeeCash or cash equivalentOPDIVO Biological, Oncology2020
2020-06-01E.R. Squibb & Sons, L.L.C.$1,000Consulting FeeCash or cash equivalent2020
2020-03-17E.R. Squibb & Sons, L.L.C.$250Consulting FeeCash or cash equivalentOPDIVO Biological, Oncology2020
2020-03-06Novocure Inc.$129Food and BeverageCash or cash equivalentOncology Device, Optune Lua2020
2020-03-05E.R. Squibb & Sons, L.L.C.$3,505Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2020
2020-02-24E.R. Squibb & Sons, L.L.C.$14Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2020
2020-02-12E.R. Squibb & Sons, L.L.C.$102Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2020
2020-02-10Merck Sharp & Dohme LLC$12Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2020
2020-02-03Genentech USA, Inc.$12Food and BeverageIn-kind items and servicesVENCLEXTA Biological, BioOncology2020
2020-01-30AstraZeneca Pharmaceuticals LP$113Food and BeverageIn-kind items and servicesTAGRISSO Drug, Oncology2020
2020-01-13Aurobindo Pharma USA, Inc.$26Food and BeverageCash or cash equivalentBeleodaq Drug, Oncology2020
2020-01-06Genentech USA, Inc.$12Food and BeverageIn-kind items and servicesAvastin Biological, BioOncology2020
2019-12-16Genentech USA, Inc.$11Food and BeverageIn-kind items and servicesVENCLEXTA Biological, BioOncology2019
2019-12-09Merck Sharp & Dohme LLC$14Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2019
2019-12-02AstraZeneca Pharmaceuticals LP$2,800Consulting FeeCash or cash equivalentIMFINZI Drug, Cardiovascular and Metabolism2019
2019-11-13AstraZeneca Pharmaceuticals LP$88Food and BeverageIn-kind items and servicesTAGRISSO Drug, Oncology2019
2019-11-11E.R. Squibb & Sons, L.L.C.$3,505Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2019
2019-11-11SEAGEN INC.$12Food and BeverageIn-kind items and services2019
2019-11-04Genentech USA, Inc.$13Food and BeverageIn-kind items and servicesGAZYVA Biological, BioOncology2019
2019-10-23E.R. Squibb & Sons, L.L.C.$96Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2019
2019-10-21Genentech USA, Inc.$11Food and BeverageIn-kind items and servicesTECENTRIQ Biological, BioOncology2019
2019-10-12AstraZeneca Pharmaceuticals LP$43Food and BeverageIn-kind items and servicesIMFINZI Drug, Oncology2019
2019-10-12AstraZeneca Pharmaceuticals LP$43Food and BeverageIn-kind items and servicesIMFINZI Drug, Oncology2019
2019-10-12AstraZeneca Pharmaceuticals LP$42Food and BeverageIn-kind items and servicesIMFINZI Drug, Oncology2019
2019-09-23E.R. Squibb & Sons, L.L.C.$12Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2019
2019-09-23E.R. Squibb & Sons, L.L.C.$12Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2019
2019-09-18Bayer Healthcare Pharmaceuticals Inc.$15Food and BeverageIn-kind items and servicesStivarga Drug, Oncology2019
2019-08-29Bayer Healthcare Pharmaceuticals Inc.$17Food and BeverageIn-kind items and servicesStivarga Drug, Oncology2019
2019-08-19Genentech USA, Inc.$18Food and BeverageIn-kind items and servicesAvastin Biological, BioOncology2019
2019-08-08Gilead Sciences, Inc.$39Food and BeverageIn-kind items and servicesZydelig Drug, ONC2019
2019-07-25E.R. Squibb & Sons, L.L.C.$3,505Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2019
2019-07-17E.R. Squibb & Sons, L.L.C.$124Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2019
2019-06-17Clovis Oncology, Inc.$12Food and BeverageIn-kind items and servicesRubraca Drug, Oncology2019
2019-06-12E.R. Squibb & Sons, L.L.C.$3,505Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOPDIVO Biological, Oncology2019
2019-06-02E.R. Squibb & Sons, L.L.C.$97Food and BeverageCash or cash equivalent2019
2019-05-31AstraZeneca Pharmaceuticals LP$91Food and BeverageIn-kind items and services2019
2019-05-31Genentech USA, Inc.$11Food and BeverageIn-kind items and servicesGAZYVA Biological, BioOncology2019
2019-05-15E.R. Squibb & Sons, L.L.C.$102Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2019
2019-05-10Bayer Healthcare Pharmaceuticals Inc.$15Food and BeverageIn-kind items and servicesStivarga Drug, Oncology2019
2019-04-29SEAGEN INC.$12EducationIn-kind items and servicesADCETRIS Biological, Oncology2019
2019-04-19Exelixis Inc.$1,960Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentCabometyx Drug, Oncology2019
2019-04-10Lilly USA, LLC$11Food and BeverageIn-kind items and servicesALIMTA Drug, Oncology2019
2019-04-01E.R. Squibb & Sons, L.L.C.$11Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2019
2019-03-30Exelixis Inc.$34Food and BeverageIn-kind items and servicesCabometyx Drug, Oncology2019
2019-03-25Clovis Oncology, Inc.$12Food and BeverageIn-kind items and servicesRubraca Drug, Oncology2019
2019-02-27AstraZeneca Pharmaceuticals LP$104Food and BeverageIn-kind items and servicesIMFINZI Drug, Cardiovascular and Metabolism2019
2019-02-21AstraZeneca Pharmaceuticals LP$32Food and BeverageIn-kind items and services2019
2019-01-21AstraZeneca Pharmaceuticals LP$32Food and BeverageIn-kind items and services2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-04-07Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$1,262A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2025
2025-02-17Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$4,800A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2025
2024-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$719A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2024
2024-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$3,095A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2024
2024-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$54,999A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2024
2024-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$6,518A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2024
2023-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$274,640A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2023
2023-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$23,704A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2023
2023-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$3,112A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2023
2023-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$3,586A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2023
2023-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$6,175A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2023
2023-01-25SEAGEN INC.Allegheny-Singer Research Institute$3,500A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast2023
2022-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$15,040A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2022
2022-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$2,608A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2022
2022-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$81,805A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2022
2022-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$2,706A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2022
2022-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$546,270A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2022
2022-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$5,078A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2022
2022-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$121,504A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2022
2022-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$5,762A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2022
2022-12-14SEAGEN INC.Allegheny-Singer Research Institute$500A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast2022
2022-09-28SEAGEN INC.Allegheny-Singer Research Institute$1,000A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast2022
2022-08-30Eli Lilly and CompanyALLEGHENY SINGER RESEARCH INSTITUTE$1,000A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF ERLOTINIB IN COMBINATION WITH RAMUCIRUMAB OR PLACEBO IN PREVIOUSLY UNTR2022
2022-07-15Novartis Pharmaceuticals CorporationALLEGHENY SINGER RESEARCH INSTITUTE$12,650A SINGLE ARM PHASE II STUDY TO EVALUATE REOCCURRENCE - FREE SURVIVAL IN CTDNA-POSITIVE STAGE III COLON CANCER PATIENTS W2022
2021-12-31AstraZeneca Pharmaceuticals LPAllegheny-Singer Research Institute$316A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio2021
2021-12-31Merck Sharp & Dohme LLCALLEGHENY SINGER RESEARCH INSTITUTE$10,805A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Beva2021
2021-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$280,144A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2021
2021-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$12,029A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2021
2021-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$110,746A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2021
2021-12-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$8,288A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2021
2021-12-31AstraZeneca Pharmaceuticals LPAllegheny-Singer Research Institute$248A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) i2021
2021-11-17Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$118,947A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2021
2021-09-03Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$51,334A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2021
2021-08-25SEAGEN INC.Allegheny-Singer Research Institute$24,900A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast2021
2021-08-23SEAGEN INC.Allegheny-Singer Research Institute$16,406A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast2021
2021-08-23SEAGEN INC.Allegheny-Singer Research Institute$32,991A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast2021
2021-08-23SEAGEN INC.Allegheny-Singer Research Institute$7,791A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast2021
2021-06-16AstraZeneca Pharmaceuticals LPAllegheny-Singer Research Institute$5,000A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio2021
2021-05-03Eli Lilly and CompanyALLEGHENY SINGER RESEARCH INSTITUTE$500A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF ERLOTINIB IN COMBINATION WITH RAMUCIRUMAB OR PLACEBO IN PREVIOUSLY UNTR2021
2021-03-19BeiGene, Ltd.ALLEGHENY SINGER RESEARCH INSTITUTE$1,500A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A32021
2021-02-09E.R. Squibb & Sons, L.L.C.Allegheny-singer Research Institute (asri)$1,800A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cance2021
2021-02-04AstraZeneca Pharmaceuticals LPAllegheny-Singer Research Institute$3,000A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) i2021
2020-12-31AstraZeneca Pharmaceuticals LPCopernicus Group Inc$785A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio2020
2020-12-31AstraZeneca Pharmaceuticals LPAllegheny-Singer Research Institute$10,308A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio2020
2020-12-31AstraZeneca Pharmaceuticals LPAllegheny-Singer Research Institute$1,037A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio2020
2020-12-14Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$39,083A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$38A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$72A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$8A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$8A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$47A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$36A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$7A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$99A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$106A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$20A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$24A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$0A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$114A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$117A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$20A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$21A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$23A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$5A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$24A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$31A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$31A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-12-08Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$36A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-11-30Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$26,055A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-11-20Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$600A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-11-19BeiGene, Ltd.ALLEGHENY SINGER RESEARCH INSTITUTE$100A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A32020
2020-11-19BeiGene, Ltd.ALLEGHENY SINGER RESEARCH INSTITUTE$1,000A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A32020
2020-11-13Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$1,900A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-10-19Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$32,569A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-10-15BeiGene, Ltd.ALLEGHENY SINGER RESEARCH INSTITUTE$750A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A32020
2020-09-28Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$750A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-09-28Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$2,814A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-09-28Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$4,240A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-09-23Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$3,800A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-09-09Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$750A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-08-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$26,055A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-08-10Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$24A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-08-10Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$23A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-08-10Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$34A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-08-10Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$35A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-08-10Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$31A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-08-10Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$2A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-08-10Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$1A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-08-10Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$27A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-08-03Merck Sharp & Dohme LLCALLEGHENY SINGER RESEARCH INSTITUTE$475A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Beva2020
2020-08-03Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$26,055A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-08-03Merck Sharp & Dohme LLCALLEGHENY SINGER RESEARCH INSTITUTE$1,207A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Beva2020
2020-07-31Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$2,032A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-07-15Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$6,122A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P2020
2020-07-15Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$250A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-07-15Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$1,500A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-07-09Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$24A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-07-09Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$0A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-07-09Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$1A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020
2020-07-09Merck Sharp & Dohme LLCALLEGHENY GENERAL HOSPITAL$19A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot2020

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Lincoln CountyDenver CDP

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Denver, NC, county Lincoln County, NC, state North Carolina; placed by its city name.

MeasurePlace (city or town)
Denver, NC
County
Lincoln County, NC
State
North Carolina
Population B010032,49792,71610,730,404
Population, 2020 census P12,69786,81010,439,388
Median age B0100238.944.439.1
Under 18 B0100120.4%20.6%21.8%
65 and over B0100111.7%19.5%17.2%
Households B110011,12236,8114,282,345
Foreign born B050020.9%5.5%9.1%
Median household income B19013$65,721$80,016$72,388
Median family income B19113$82,898$95,817$90,290
Per capita income B19301$37,980$44,098$41,385
Poverty rate B170016.0%11.2%13.0%
Unemployment rate B230252.6%3.3%4.7%
Civilian labor force B230251,46446,2385,336,863
Mean commute (minutes) B0801329.429.325.1
Bachelor's degree or higher B1500343.6%28.3%35.7%
Housing units B250011,17039,5044,895,668
Owner-occupied B2500355.2%78.9%66.6%
Renters B2500344.8%21.1%33.4%
Median home value B25077$296,300$321,000$288,900
Median gross rent B25064$869$1,015$1,228
White, not Hispanic B0300286.7%82.0%60.0%
Black B030020.0%5.9%20.0%
Hispanic or Latino B030020.3%8.1%11.3%
Asian B030020.0%0.8%3.3%
American Indian and Alaska Native B030020.0%0.1%0.8%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Denver, NC.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.